Cooperative Agreement UG3CA299397
Award Date 8/1/25
Completion Date 7/31/28
Dollars Obligated $323K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Michigan, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,623,261 to Case Western Reserve University to conduct a clinical trial and develop novel molecular technologies for early detection and prevention of esophageal adenocarcinoma. Specifically, the project aims to: 1) demonstrate the efficacy of a non-endoscopic, biomarker-based approach to detect Barrett's esophagus, a precursor to esophageal cancer, in a population...
- This $3,130,492 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to improve understanding of the fundamental biological mechanisms driving the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EA), a highly lethal cancer. The project, conducted by Arizona State University, aims to develop computational methods to analyze the spatial structure and cell type diversity in BE tissue biopsies in...
- This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $398,398 to Cold Spring Harbor Laboratory (CSHL) to conduct research on identifying natural product-derived inhibitors of the KLK6 enzyme as a strategy to prevent the progression of preneoplastic ductal pancreatic cancer. The funding supports a multi-year project to leverage CSHL's expertise in cancer biology, genomics, and computational...
- This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $456,764 to the University of Chicago to study differences in bile acid metabolism and responses between African Americans and non-Hispanic whites. The goal is to determine if these differences could contribute to the higher colorectal cancer incidence and mortality rates observed in the African American population. Specifically, the research will: 1) compare serum...
- The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...
- The National Cancer Institute (NCI), a division of the Department of Health and Human Services, awarded Drexel University a $588,359 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant, which runs from May 19, 2025 to April 30, 2030, will evaluate the efficacy of a multi-level intervention, referred to as "EATWELL", designed to promote adherence to the dietary guidelines for cancer prevention recommended by the World Cancer Research Fund and...
- This Cooperative Agreement award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The $692,491 award, effective May 1, 2025 through April 30, 2030, will allow the University of Chicago to explore cancer-specific early epigenetic marks in circulating cell-free DNA and develop a highly sensitive...
- This federal Project Grant award, valued at $682,272.00, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award will fund a research project entitled "Assessing Feasibility and Acceptability of a Multifaceted EHR-Integrated Mobile Health Intervention Following Radical Cystectomy" at the University of Michigan. The goal of the project is to develop and evaluate a novel, technology-enabled intervention to reduce...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $675,867 to the Medstar Health Research Institute Inc. to improve the delivery of practical geriatric assessment in community oncology settings. The goal is to increase the use of geriatric assessment, which can help mitigate adverse outcomes for older cancer patients, in clinics with limited specialized resources. The project will compare standard ASCO educational...